<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01813955</url>
  </required_header>
  <id_info>
    <org_study_id>Papaverine schizophrenia</org_study_id>
    <nct_id>NCT01813955</nct_id>
  </id_info>
  <brief_title>Phosphodiesterase (PDE) Inhibitors Effect on Cognitive Deficits Associated to Schizophrenia</brief_title>
  <official_title>PDE Inhibitors Effect on Cognitive Deficits Associated to Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Glostrup University Hospital, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phosphodiesterase (PDE) inhibitors represent a new group of potential antipsychotic compounds&#xD;
      currently under development. One of these is papaverine, an inhibitor of the PDE 10 family.&#xD;
      The class of PDE10 inhibitors have been reported as possible candidates in the treatment of&#xD;
      schizophrenia, and may prove an attractive antipsychotic alternative due to the many&#xD;
      side-effects of the currently available antipsychotics. It has been proposed from preclinical&#xD;
      studies that PDE10 inhibitors have the potential to reduce cognitive deficits in&#xD;
      schizophrenia and these findings need to be confirmed in a human population, in view of the&#xD;
      fact that no other currently registered drug posses these unique properties.&#xD;
&#xD;
      The currently proposed project is designed to investigate whether the PDE10 inhibitor&#xD;
      Papaverine indeed have the capacity to reduce cognitive deficits in schizophrenia patients.&#xD;
      In order to accomplish this effect, Papaverine will be investigated in schizophrenia, with&#xD;
      regards to symptomatology, hemodynamic, neurocognition and early information-processing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study has a double blind, balanced crossover design. Randomized, half of the subjects&#xD;
      will be given Papaverine (PDE10 inhibitor, 300 mg orally) in the first session followed by&#xD;
      placebo in the second, and the other half will be treated in the reverse order. There is a&#xD;
      minimum of one month between the two test-sessions. After each of the two treatments, the&#xD;
      subjects will be tested with both a psychophysiological (the Copenhagen Psychophysiological&#xD;
      Test-Battery) and neuropsychological test-battery (tests from the Cambridge&#xD;
      Neuropsychological Test Automated Battery, or &quot;CANTAB&quot;). The project has three phases: In the&#xD;
      first phase 10 healthy subjects will be included to determine the kinetics of&#xD;
      Papaverine-contained release capsules ; in the second phase 30 schizophrenia patients and 30&#xD;
      healthy subjects will be included to determine the impact on cognitive and sensory gating&#xD;
      related deficits; Finally 10 Healthy subjects will be included to determine the effect of&#xD;
      Papaverine on hemodynamical parameters by the means magnetic resonance scannings.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Patient recruitment insufficient&#xD;
  </why_stopped>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>psychophysiology</measure>
    <time_frame>1 hour after intake of capsule with papaverine or placebo</time_frame>
    <description>Prepulse inhibition of the startle reflex, Mismatch negativity, P300 amplitude</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic changes</measure>
    <time_frame>1 hour after intake of capsule with papaverine or placebo</time_frame>
    <description>Changes in Hemodynamics, as observed by MR techniques</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Cognitive Deficits</condition>
  <arm_group>
    <arm_group_label>Papaverine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive either Papaverine or placebo added to their current medical treatment. Then after one week, they will receive the other treatment (if it was placebo first, then it will be papaverine; if it was papaverine first, then it will be placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Papaverine or placebo</intervention_name>
    <description>Papaverine delayed release (depot capsule, 300 mg, orally, one single dosage per subject) or placebo</description>
    <arm_group_label>Papaverine</arm_group_label>
    <other_name>Papaverine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed Schizophrenia (WHO ICD 10)&#xD;
&#xD;
          -  Treatment stable (no regulation in medicine for 6 weeks prior)&#xD;
&#xD;
          -  Mono antipsychotic treatment&#xD;
&#xD;
          -  No regular Antidepressants (PN accepted)&#xD;
&#xD;
          -  No regular Benzodiazepines (PN accepted)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dependence syndrome&#xD;
&#xD;
          -  Severe physical illness&#xD;
&#xD;
          -  MRI incompatible, non removable objects above shoulders&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Birte Glenthøj, Professor</last_name>
    <role>Study Director</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mikkel E Sørensen, PHD student</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bob Oranje, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Center for Neuropsychiatric Schizophrenia Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glostrup psychiatric center</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>September 19, 2011</study_first_submitted>
  <study_first_submitted_qc>March 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2013</study_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Birte Glenthoj</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>phosphodiesterase inhibitor</keyword>
  <keyword>Psychophysiology</keyword>
  <keyword>Cognition</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Papaverine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papaverine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

